$sls glad I sold that pop first thing. $Capr I won't. The street will take some days to see the impact and funds will scoop more up. Expect a 2027 buy out.
$CAPR In the US alone there are 10,000 young men in wheelchairs who can benefit from Deramiocel.
The peer reviewed Lancet article stated both skeletal and cardiac muscle benefit (pp.2,9)
The Robustness analysis said the benefits are not "fragile"...they are ROBUST !
The American Heart Association Award is for the cardiac benefit !
All the DMD families want is for their boys to have better quality and longer lives. That is what we all want for our kids!
The FDA says they want to treat rare diseases fairly...now let them do what they say!
Bullish
$CAPR Everyone is talking about Tangβs exit, but has anyone noticed that RA Capital doubled its position and that Perceptive and EcoR1 initiated stakes in the company, investing several million dollars? To me, this is one of the most bullish signals from the past quarter.
$PMCB recall that the company is currently trading near $6 while holding approximately $31 in net cash per share with a micro float of roughly 566,000 shares.
I ran a forensic linguistic and behavioral breakdown on CEO Linda MarbΓ‘nβs Q3 earnings call ahead of $CAPRβs Nov 22 FDA decision. Looking at her exact wording, tone, and rhythm reveals three major clues:
Relaxed Q&A Rhythm (Zero Panic): Her prepared script was tight and lawyer-vetted, but in live Q&A she relaxed and joked ("I am being a little silly... right now, we are thinking we are done"). CEOs facing a hostile FDA fight or imminent CRL don't crack jokes 12 days outβit signals the review file is quiet and complete.
The "Labeling" Word Choice: When asked if heart data makes the label, she didn't say "we haven't discussed a label." She said "we are not disclosing the label information at this point"βand added whether cardiac is "in the label now or a future label expansion," signaling that a narrow upper-limb (PUL 2.0) label is the primary path.
Actions Speak Louder Than Legal Hedges: She used standard legal disclaimers ("if and when," "lucky enough"), yet $CAPR ramped Q3 spending to $44.7M to build patient support and payer access for a solo launch.
No CEO can guarantee an FDA signature, but every behavioral tell says the review reached the finish line cleanly.